Vaxil Bio Ltd (TSE:VXL)
:VXL
Want to see TSE:VXL full AI Analyst Report?
Top Page
Vaxil Bio
(VXL)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.18
▲(34.62% Upside)
Action:Reiterated
Date:06/06/26
The score is primarily held down by weak financial performance (no revenue, ongoing operating losses, and consistent cash burn) and bearish technical momentum (oversold readings with negative MACD and price below short-term averages). A low-debt balance sheet and a low reported P/E provide some offset, but not enough to materially improve the risk profile.
Positive Factors
Low leverage / stronger equity base
The company's effectively no-debt position and increased equity in 2025 reduce financial distress risk and preserve strategic flexibility. Low leverage lowers mandatory financing costs, improves ability to pursue clinical programs or partnerships, and lengthens runway versus peers reliant on debt.
Negative Factors
No commercial revenue
As a pre-commercial biotech with no product revenue and negative EBIT/EBITDA, Vaxil must rely on external funding or partnerships to continue operations. Lack of recurring commercial cash flow increases execution risk and makes long-term viability contingent on successful clinical outcomes or deal-making.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / stronger equity base
The company's effectively no-debt position and increased equity in 2025 reduce financial distress risk and preserve strategic flexibility. Low leverage lowers mandatory financing costs, improves ability to pursue clinical programs or partnerships, and lengthens runway versus peers reliant on debt.
Read all positive factors
Vaxil Bio (VXL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$717.12K
Dividend YieldN/A
Average Volume (3M)1.45K
Price to Earnings (P/E)1.4
Beta (1Y)-1.00
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaxil Bio Business Overview & Revenue Model
Company Description
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically inf...
How the Company Makes Money
As a clinical-stage biotechnology company, Vaxil Bio’s ability to generate recurring commercial revenue from product sales is not publicly verifiable here; null. In general, companies at this stage typically fund operations through a combination o...
Vaxil Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
32
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -2.00K | -25.00K |
| EBITDA | -179.00K | -178.00K | -252.00K | -582.00K | -961.00K |
| Net Income | 522.00K | -178.00K | -254.00 | -584.00K | -986.00K |
Balance Sheet | |||||
| Total Assets | 1.37M | 733.00K | 976.00K | 1.54M | 2.29M |
| Cash, Cash Equivalents and Short-Term Investments | 671.00K | 714.00K | 938.00K | 1.51M | 2.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.00K | 17.00K | 85.00K | 405.00K | 585.00K |
| Stockholders Equity | 1.36M | 716.00K | 891.00K | 1.14M | 1.70M |
Cash Flow | |||||
| Free Cash Flow | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Operating Cash Flow | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Investing Cash Flow | 266.00K | -250.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 127.00K | 0.00 | 0.00 | 0.00 | 1.81M |
Vaxil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$5.74M | -0.16 | 123.88% | ― | ― | 60.66% | |
44 Neutral | C$717.12K | 1.37 | -10.30% | ― | ― | ― | |
44 Neutral | C$37.84M | -0.25 | -221.75% | ― | ― | 85.31% | |
41 Neutral | C$27.84M | -2.61 | -103.51% | ― | ― | -42.77% | |
| ― | C$2.04M | -0.59 | ― | ― | ― | 25.09% | |
41 Neutral | C$37.89M | -4.48 | ― | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:VXL
Vaxil Bio
0.18
-0.02
-10.00%
TSE:APS
Aptose Biosciences
2.25
1.10
95.65%
TSE:MDNA
Medicenna Therapeutics Corp
0.41
-0.44
-52.35%
TSE:BCT
BriaCell Therapeutics
4.35
-35.65
-89.13%
TSE:BIOV
BioVaxys Technology
0.07
-0.28
-80.00%
TSE:DTC
Defence Therapeutics
0.50
-0.20
-28.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.